A Study of LY4257496 in Participants With Cancer (OMNIRAY)

2025-522367-15-00 · tracked via the Priya Life Science EU tracker

Sponsor

Eli Lilly & Co.

Sponsor type

Pharmaceutical company

Therapeutic area

Neoplasms

Decision date

05/03/2026

Enrollment target

Sites

Germany

Condition studied

Breast Neoplasms Colorectal Neoplasms Prostate Neoplasm Endometrial Neoplasms Neoplasm Metastasis Stomach Neoplasms Esophageal Neoplasms

Eligibility

Age group

65+ years, 18-64 years

Sex

Female, Male

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-522367-15-00 on CTIS ↗ ← All trials in the EU